The growing prevalence of chronic genetic disorders and rising healthcare costs in both developed and developing countries are expected to fuel growth in the regenerative medicine industry. Additionally, the market is expected to expand as a result of major players' strategic initiatives to integrate AI into drug development. WESTFORD, Mass., Sept. 1, 2025 /PRNewswire/ -- SkyQuest Technology Consulting published a report, titled, Regenerative Medicine Market - Global Opportunity Analysis and In

CHICAGO, Sept. 1, 2025 /PRNewswire/ -- In a groundbreaking milestone for global healthcare and pharmaceutical innovation, Professor Sarfaraz K. Niazi, Adjunct Professor at the University of Illinois at Chicago and founder of multiple biopharmaceutical enterprises, has secured the first-ever FDA acceptance to waive clinical efficacy studies (CESs) for monoclonal antibody biosimilars. This decision fundamentally redefines how biological drugs will be developed, approved, and made affordable for pa

"Quantum AI up to 73x Faster on NVIDI A CUDA-Q" Norma, a quantum computing company, has validated the performance of quantum AI algorithms using NVIDIA CUDA-Q. By running these algorithms for drug development on CUDA-Q, Norma observed computational speeds up to 73 times faster. The company has secured use cases for quantum AI in drug development and plans to expand validation efforts into various fields. SEOUL, South Korea, Sept. 1, 2025 /PRNewswire/ -- Quantum computing company Norma (CEO

Oslo University Hospital announces the startup of a multicentre randomized phase 2 trial of ILB® in ALS, commencing early 2026. The study will compare ILB® to Riluzole, the current standard of care, and will include 116 patients over a 12-month study period. VIKEN, Sweden, Sept. 1, 2025 /PRNewswire/ -- Senior consultant neurologist Dr Angelina Hatlø Maniaol is coordinating investigator for the study, which will consist of a 6-month double-blind randomized phase where patients will get either Ril

Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score U.S. regulatory submission for cemdisiran monotherapy is planned for the first quarter of 2026, pending discussions with the FDA TARRYTOWN, N.Y. , Aug. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary and key sec

New institution is now third-largest public research university in Texas SAN ANTONIO, Sept. 1, 2025 /PRNewswire/ -- UTSA and The University of Texas Health Science Center at San Antonio (UT Health San Antonio) today merged to form The University of Texas at San Antonio (UT San Antonio), a premier global university that is deeply committed to making lives better for the communities it serves. As a merged institution, UT San Antonio now ranks as the third-largest public research university in Tex

ZUG, Switzerland, Sept. 1, 2025 /PRNewswire/ -- Berlin Heals Holding AG, a MedTech company, is developing a novel treatment to reverse remodel and recover from Heart Failure. After a successful First-In-Human study in 2019 followed by sustaining long-term results and a successful Randomized Controlled Trial completed in 2024, the company has been developing a new approach to implant the device less invasively in an outpatient cardiac cath lab procedure. The implant consists of two electrodes con

Roche’s Genentech unit and Alnylam will kick off a Phase III cardiovascular (CV) outcomes trial for zilebesiran in uncontrolled hypertension later this year, despite the investigational RNAi therapeutic flunking KARDIA-3 — the last of three mid-stage studies in the KARDIA programme.Highlighting the urgent need for additional treatment options, Roche’s Chief Medical Officer Levi Garraway said that “zilebesiran has the potential to become a best-in-disease treatment for many patients with uncontro

Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) cut the risk of major adverse cardiovascular events (MACE) by over 50% compared with Eli Lilly’s GIP/GLP-1 co-agonist Zepbound (tirzepatide) in individuals with overweight or obesity and cardiovascular disease (CV) who maintained treatment, according to new real-world data presented at the European Society of Cardiology (ESC) congress this weekend.The Danish company noted that results from the STEER observational trial build upon the 20% CV risk

Just over two years after being put up for sale by its owners, Stada Arzneimittel is set to be acquired by buyout firm CapVest Partners for around €10 billion ($11.7 billion), Bloomberg reported. According to people close to the matter, Stada's private equity owners Bain Capital and Cinven are in the process of finalising terms of an agreement with CapVest. Bain and Cinven — which took over Stada in a deal worth €5.3 billion in 2017 — began exploring options for the generic drugmaker in August 2